Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
Alexion Pharmaceuticals’ Voydeya (danicopan) became the first medicine to be eligible for a new “early launch premium” introduced under Japan’s FY2024 drug pricing reform. However, the premium was entirely removed due to its low cost disclosure ratio. Voydeya was among…
To read the full story
Related Article
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
- Rapalimus Granules Now Available in Japan: Nobelpharma
July 9, 2024
- Lilly Rolls Out Eczema Drug Ebglyss in Japan
June 3, 2024
- AnGes to Roll Out Progeria Treatment Zokinvy on May 27
May 24, 2024
- BMS’ Reblozyl Now Available in Japan for Anemia in MDS
May 21, 2024
- Pfizer’s PARP Inhibitor Talzenna Now Available in Japan
April 24, 2024
- Voydeya, High-Dose Eylea, Vyvdura and More Now Available in Japan
April 18, 2024
- Nobelpharma, Argenx Challenged Initial Pricing for New Meds; Claims Partially Accepted
April 11, 2024
- Japan Approves Pfizer’s RSV Jab, Ultragenyx’s Evkeeza, and More
January 19, 2024
REGULATORY
- JPMA Urges Foreign Price Rule Overhaul to Address US MFN Policy: LDP Hearing
November 5, 2026
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- PMDA Sets Out AI Principles for Regulatory Activities, Stresses Human Oversight
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…